Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.680
+0.100 (6.33%)
At close: Jun 26, 2026, 4:00 PM EDT
1.640
-0.040 (-2.38%)
After-hours: Jun 26, 2026, 6:58 PM EDT
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 10.67, with a low estimate of 7.00 and a high estimate of 19. The average target predicts an increase of 535.12% from the current stock price of 1.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Jeff Jonas Gabelli No rating | Gabelli | Buy Initiates $8 | Buy | Initiates | $8 | +376.19% | Jun 15, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $8 | Buy | Initiates | $8 | +376.19% | Jun 15, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $7 | Buy | Reiterates | $7 | +316.67% | May 16, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $19 | Buy | Reiterates | $19 | +1,030.95% | May 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
145.50K
EPS This Year
-2.07
from -2.02
EPS Next Year
-1.95
from -2.07
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 1.2M | |
| Avg | n/a | 145,500 | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 27,391.4% |
| Avg | - | 11,652.6% |
| Low | - | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.68 | -1.11 | |
| Avg | -2.07 | -1.95 | |
| Low | -2.50 | -2.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.